Supratherapeutic posaconazole concentration in a pediatric transplant patient with confirmed rhizopus infection

Christine A. Vu, Mariawy Riollano-Cruz, Shanna R. Kowalsky

Research output: Contribution to journalArticlepeer-review


There are a limited number of studies that guide dosing of posaconazole delayed-release (DR) tablets for the pediatric population. Current FDA-approved doses are only recommended for patients 13 years and older. For younger patients, providers are faced with the challenge of recommending posaconazole doses extrapolated from adult studies or choosing an alternative agent. We report on a case of a 10-year-old patient who experienced a supratherapeutic trough serum concentration and transaminitis after receiving the extrapolated adult dosage of posaconazole DR tablets (300 mg twice daily for the first day, followed by 300 mg daily) for 7 days. In the end, the patient required a smaller dose of 200 mg daily to achieve the desired trough target concentration for the treatment of a Rhizopus neck infection. Our findings highlight the need for additional studies to determine the optimal dosing of posaconazole DR tablets for children. ABBREVIATIONS ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DR, delayed-release; FDA, US Food and Drug Administration.

Original languageEnglish
Pages (from-to)753-757
Number of pages5
JournalJournal of Pediatric Pharmacology and Therapeutics
Issue number7
StatePublished - 2021


  • Invasive fungal infections
  • Posaconazole
  • Rhizopus
  • Supratherapeutic


Dive into the research topics of 'Supratherapeutic posaconazole concentration in a pediatric transplant patient with confirmed rhizopus infection'. Together they form a unique fingerprint.

Cite this